02.01.2014 • NewsChinaIPO

China Clears 2nd Batch of IPOs After Ending Listing Freeze

China has approved six more companies to list on mainland stock exchanges, the second batch to get approval since regulators ended a year-long freeze on initial public offerings, state media reported on Thursday.

The China Securities Regulatory Commission (CSRC) gave the green light to six companies on Tuesday, including Shaanxi Coal and Chemical Industry Group, Shanghai Liangxin Electrical, Being UTour International Travel Service Co Ltd, the official China Securities Journal reported.
Shaanxi Coal is the largest among the six and had already received preliminary CSRC approval for an IPO prior to the suspension. It had planned to raise around 17.2 billion yuan ($2.84 billion).

That would make it the largest Chinese IPO since Agricultural Bank of China debuted in 2010.
The latest approvals follow an initial batch of five approvals earlier this week.

The long-awaited resumption of the IPO market is a boon to the more than 750 companies whose applications are pending with the regulator but will bring trepidation to equity investors, who fear new listings will siphon off demand from existing shares.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.